# **Genentech® Access to Care Foundation (GATCF)** for **FUZEON®** (enfuvirtide)

### Statement of Medical Necessity (SMN)

Please write legibly and complete all required fields (\*) to prevent delays.

**DIAGNOSIS/TREATMENT** 

**PRESCRIPTION** 

M-US-00006697(v1.0) 08/20

Filone: (800) 247-3084 Fax: (800) 303-1830			יו	W-03-00000097(VI:0) 08/20	
Last name*:	First name*:	Birth date	*:	Gender*: ☐ Male ☐ Female	
Street:	City: _		State*:	ZIP:	
Home phone: ()	Work/cell phone: (	))	Email:		
Alternate contact last name:	First name:		Phone: (	)	
Relationship to patient: OK to contact patient? $\square$ Yes $\square$ No Preferred language (if other than English):					
□ HMO/EPO □ POS □ POS □ Medicare/Medicaid □ PBM □ Pending Insurance denial/non-coverage policy atta Primary insurance (PI) name: □ PI phone: □ PI subscriber name: □ PI subscriber ID #: □ Policy/group #: □ Insurance card attached? □ Yes □ No	□ HMO/EPO □ PPO □ POS □ Indemnity □ Medicare/Medicaid □ PBM □ Pending Medicaid □ No insurance Insurance denial/non-coverage policy attached? □ Yes □ No Secondary insurance (SI) name:  SI phone: □ SI subscriber name: □ Policy/group #: □ Insurance card attached? □ Yes □ No				
DIAGNOSIS CODE (highest level of specificity)*: □ B20/042 Human Immunodeficiency Virus (HIV) disease □ Other					
Dose: mg Dispense: 90-mg/mL convenience pack					
Prescriber's last name*:		First name			
Practice name:					
Street*:	City*:		State*:	ZIP*:	
Phone: ()					
Prescriber Tax ID:					
Group NF					
Reimbursement/clinical contact last name					
Reimbursement/clinical contact phone: (_					
PHYSICIAN CERTIFICATION: By signing below, I certify: (a) the defined by the Health Insurance Portability and Accountability the purpose of requesting reimbursement support, assisting in therapeutic outcome and (c) I will not attempt to seek reimbur alternative site of administration chosen by the above-named parts.	e above therapy is medically necessary, (b) I r kct of 1996 (HIPAAI) to Genentech, Inc., Gener initiating or continuing therapy and/or the evalu sement for free product provided directly to th	eceived the authorization to rele tech Access Solutions, the contra tation of the patient's eligibility for patient or an alternative site of	ease the information above and acted dispensing pharmacy, info or GATCF, as a break in treatme care. I request Genentech Acc	other protected health information (as usion site of care or other contractors for nt would negatively impact the patient's ses Solutions convey to the pharmacy or	

effined by the Health Insurance Portability and Accountability Act of 1996 (HIPAA) to Genentech, Inc., Genentech Access Solutions, the contracted dispensing pharmacy, infusion site of care or other contractors for the purpose of requesting reimbursement support, assisting in initiating or continuing therapy and/or the evaluation of the patient's eligibility for GATCF, as a break in treatment would negatively impact the patient's therapeutic outcome and (c) I will not attempt to seek reimbursement for free product provided directly to the patient or an alternative site of care. I request Genentech Access Solutions convey to the pharmacy or alternative site of administration chosen by the above-named patient the prescription described herein. I agree to comply with the Genentech, Inc., program guidelines and understand that Genentech and GATCF, at its sole discretion, reserves the right to modify or discontinue the program at any time and to verify the accuracy of the information submitted. I further understand that Genentech will provide vial replacement in a configuration that will create the least wastage. If applying for GATCF, I certify that (a) this patient has no medical insurance coverage or otherwise meets the financial criteria for the prescribed therapy, and is not considered an authorized prescriber. For prescribers in states with official prescription form requirements, such as New York, please submit prescriptions on an official state prescription blank along with this form. Unapproved Use Warning: Please read the FDA-approved label for Genentech products before prescribing, If the indication for which you are prescribing a Genentech product is not listed in the FDA approved label, you are prescribing the medication for a "unapproved" use, meaning that the FDA has not approved the efficacy, dosage amount or safety of this medication for such a use. Nevertheless, GATCF will consider providing the medication for your patient with this admonition, based upon your medical order, within program requireme

Prescriber's Signature*		Date*
<b>C</b>	(Original signature required. This form cannot be processed without a prescriber's signature.)	

## Genentech® Access to Care Foundation (GATCF) Statement of Medical Necessity (SMN) for FUZEON® (enfuvirtide)

Please write legibly and complete all required fields (\*) to prevent delays.

#### **DIAGNOSIS/TREATMENT**

- Check the appropriate Diagnosis Code
- If "Other" is checked, specify the diagnosis code to the highest level of specificity
- For dates of service prior to October 1, 2015, ICD-9-CM codes must be used. For dates of service on or after October 1, 2015, only ICD-10-CM codes will be accepted

#### **PRESCRIPTION**

Complete the dose and refill fields along with the dispense instructions

#### **PRESCRIBER**

Stamped prescription signatures are not accepted

#### **GATCF REQUIRED FIELDS**

- All GATCF required fields are indicated with an asterisk (\*)
- GATCF cannot process your SMN unless these fields are completed

#### ATTACH TO COMPLETED SMN

 Attach signed and dated Patient Authorization and Notice of Release of Information (PAN) for FUZEON. GATCF cannot work on your patient's behalf without these signed and dated forms

PROVIDING ADDITIONAL DOCUMENTS OR INFORMATION WITH THIS FORM, OTHER THAN WHAT IS REQUESTED, WILL DELAY PROCESSING.

**REMINDER:** This form cannot be processed without a prescriber's signature and date, as well as a signed and dated PAN form.

Phone: (866) 247-5084 Fax: (800) 305-1830

